CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Sanofi SA - SAN CFD

95.44
1.65%
0.36
Low: 94.54
High: 95.76
Market Trading Hours* (UTC) Open now
Closes on Wednesday at 15:30

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.36
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.019974 %
Charges from borrowed part ($-0.80)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.019974%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.002248 %
Charges from borrowed part ($-0.09)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.002248%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 20%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Sanofi SA ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 94.07
Open* 94.54
1-Year Change* -5.38%
Day's Range* 94.54 - 95.76
52 wk Range 76.45-105.18
Average Volume (10 days) 1.32M
Average Volume (3 months) 35.87M
Market Cap 119.05B
P/E Ratio 14.19
Shares Outstanding 1.25B
Revenue 46.20B
EPS 6.65
Dividend (Yield %) 3.77479
Beta 0.47
Next Earnings Date Jul 28, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 30, 2023 94.07 -1.43 -1.50% 95.50 96.37 93.84
May 29, 2023 98.66 0.52 0.53% 98.14 99.14 98.14
May 26, 2023 99.17 0.77 0.78% 98.40 99.36 97.94
May 25, 2023 98.30 -1.56 -1.56% 99.86 100.60 98.20
May 24, 2023 100.56 0.14 0.14% 100.42 101.42 100.18
May 23, 2023 100.72 0.92 0.92% 99.80 100.90 99.48
May 22, 2023 100.08 -1.26 -1.24% 101.34 101.94 99.88
May 19, 2023 101.42 1.79 1.80% 99.63 101.88 99.63
May 18, 2023 99.64 0.65 0.66% 98.99 99.86 98.99
May 17, 2023 98.60 -1.32 -1.32% 99.92 99.96 98.41
May 16, 2023 100.10 0.99 1.00% 99.11 100.20 99.08
May 15, 2023 99.54 -0.06 -0.06% 99.60 100.44 99.28
May 12, 2023 99.04 -0.27 -0.27% 99.31 100.28 98.88
May 11, 2023 98.97 -0.38 -0.38% 99.35 99.81 98.44
May 10, 2023 98.29 -1.44 -1.44% 99.73 99.86 98.04
May 9, 2023 100.48 0.28 0.28% 100.20 100.80 99.71
May 8, 2023 100.00 -0.68 -0.68% 100.68 100.94 99.71
May 5, 2023 101.38 2.20 2.22% 99.18 101.38 99.05
May 4, 2023 99.10 0.97 0.99% 98.13 99.53 97.50
May 3, 2023 97.70 0.86 0.89% 96.84 97.72 96.21

Sanofi SA Events

Time (UTC) Country Event
Thursday, June 29, 2023

Time (UTC)

12:00

Country

FR

Event

Sanofi SA Vaccines Investor Event
Sanofi SA Vaccines Investor Event

Forecast

-

Previous

-
Friday, October 27, 2023

Time (UTC)

05:30

Country

FR

Event

Q3 2023 Sanofi SA Earnings Release
Q3 2023 Sanofi SA Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 45389 39175 37369 37631 35677
Revenue 45389 39175 37369 37631 35677
Cost of Revenue, Total 13695 12255 12159 11979 11435
Gross Profit 31694 26920 25210 25652 24242
Total Operating Expense 34733 31049 23256 34580 31001
Selling/General/Admin. Expenses, Total 10410 9457 9304 9777 9772
Research & Development 6705 5689 5528 6017 5890
Depreciation / Amortization 2140 1681 1774 2262 2264
Unusual Expense (Income) -581 235 777 3966 1696
Other Operating Expenses, Total 2391 1728 1220 817 61
Operating Income 10656 8126 14113 3051 4676
Interest Income (Expense), Net Non-Operating -167 -289 -263 -210 -273
Other, Net -67 -39 -72 -89 2
Net Income Before Taxes 10422 7798 13778 2752 4405
Net Income After Taxes 8416 6240 11971 2631 3924
Minority Interest -113 -56 -36 -31 -104
Equity In Affiliates 68 39 359 255 499
Net Income Before Extra. Items 8371 6223 12294 2855 4319
Total Extraordinary Items 0 0 -101 -13
Net Income 8371 6223 12294 2754 4306
Income Available to Common Excl. Extra. Items 8371 6223 12294 2855 4319
Income Available to Common Incl. Extra. Items 8371 6223 12294 2754 4306
Dilution Adjustment
Diluted Net Income 8371 6223 12294 2754 4306
Diluted Weighted Average Shares 1256.9 1257.9 1260.1 1257.1 1255.2
Diluted EPS Excluding Extraordinary Items 6.66004 4.94713 9.75637 2.2711 3.44089
Dividends per Share - Common Stock Primary Issue 3.56 3.31263 3.2 3.15 3.07
Diluted Normalized EPS 6.28676 5.09663 10.2921 5.28727 4.64452
Interest Expense (Income) - Net Operating -27 4 -7506 -238 -117
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 10863 24594 13138 20795 10053
Revenue 10863 24594 13138 20795 10053
Cost of Revenue, Total 3079 7565 3831 6130 2880
Gross Profit 7784 17029 9307 14665 7173
Total Operating Expense 8400 17767 10414 16966 7656
Selling/General/Admin. Expenses, Total 2607 5539 2644 4953 2379
Research & Development 1563 3559 1736 3147 1489
Depreciation / Amortization 489 1143 460 910 449
Unusual Expense (Income) 343 231 1955 1021 198
Other Operating Expenses, Total 304 -226 -180 788 265
Operating Income 2463 6827 2724 3829 2397
Interest Income (Expense), Net Non-Operating -7 -62 -51 -135 -78
Net Income Before Taxes 2456 6748 2673 3674 2319
Net Income After Taxes 1997 5237 2072 3179 1987
Minority Interest -14 -60 -3 -53 -8
Equity In Affiliates 12 10 7 58 30
Net Income Before Extra. Items 1995 5187 2076 3184 2009
Net Income 1995 5187 2076 3184 2009
Income Available to Common Excl. Extra. Items 1995 5187 2076 3184 2009
Income Available to Common Incl. Extra. Items 1995 5187 2076 3184 2009
Diluted Net Income 1995 5187 2076 3184 2009
Diluted Weighted Average Shares 1249.3 1258.5 1253.5 1255.3 1249.2
Diluted EPS Excluding Extraordinary Items 1.59689 4.12157 1.65616 2.53645 1.60823
Dividends per Share - Common Stock Primary Issue 0 3.56 0 0 0
Diluted Normalized EPS 1.82014 4.26402 2.86513 3.24021 1.74404
Interest Expense (Income) - Net Operating 15 -44 -32 17 -4
Other, Net -17 -20
Total Extraordinary Items
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 34026 30564 33703 28611 24579
Cash and Short Term Investments 13400 11152 14815 9853 7124
Cash 1385 1358 1144 701 661
Cash & Equivalents 11351 8740 12771 8726 6264
Short Term Investments 664 1054 900 426 199
Total Receivables, Net 10746 9787 9953 10083 9345
Accounts Receivable - Trade, Net 8424 7568 7491 7937 7260
Total Inventory 8960 8715 8352 7994 7477
Prepaid Expenses 714 615 525 493 469
Other Current Assets, Total 206 295 58 188 164
Total Assets 126722 120242 114413 112630 111408
Property/Plant/Equipment, Total - Net 11684 11976 10563 11017 9651
Property/Plant/Equipment, Total - Gross 26796 27555 24880 25151 22697
Accumulated Depreciation, Total -15112 -15579 -14317 -14134 -13046
Goodwill, Net 49892 48056 44364 44519 44235
Intangibles, Net 21640 21407 18341 16509 21889
Long Term Investments 2765 2425 2129 5303 5550
Note Receivable - Long Term 452 485 537 521 746
Other Long Term Assets, Total 6263 5329 4776 6150 4758
Total Current Liabilities 23964 21295 19248 20381 17376
Accounts Payable 6813 6180 5295 5313 5041
Accrued Expenses 2158 2126 2042 1978 1989
Notes Payable/Short Term Debt 168 189 285 305 249
Current Port. of LT Debt/Capital Leases 4287 3263 2714 4508 2364
Other Current Liabilities, Total 10538 9537 8912 8277 7733
Total Liabilities 51938 51561 51307 53574 52532
Total Long Term Debt 17047 19015 20725 21168 22071
Long Term Debt 15143 17176 19794 20181 22053
Capital Lease Obligations 1904 1839 931 987 18
Deferred Income Tax 1841 1617 1770 2294 3414
Minority Interest 368 350 146 174 159
Other Liabilities, Total 8718 9284 9418 9557 9512
Total Equity 74784 68681 63106 59056 58876
Common Stock 2522 2527 2518 2508 2495
Additional Paid-In Capital 66859 63545 60511 52049 53106
Treasury Stock - Common -706 -939 -705 -9 -153
Other Equity, Total 6109 3548 782 4508 3428
Total Liabilities & Shareholders’ Equity 126722 120242 114413 112630 111408
Total Common Shares Outstanding 1252.64 1252.54 1250.69 1253.83 1245.45
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 34026 28360
Cash and Short Term Investments 12736 6899
Cash & Equivalents 12736 6899
Total Receivables, Net 8798 8406
Accounts Receivable - Trade, Net 8424 7868
Total Inventory 8960 9366
Other Current Assets, Total 3532 3689
Total Assets 126722 121826
Property/Plant/Equipment, Total - Net 11684 11642
Goodwill, Net 49892 50555
Intangibles, Net 21640 21978
Long Term Investments 2765 2650
Note Receivable - Long Term 452 641
Other Long Term Assets, Total 6263 6000
Total Current Liabilities 23964 22060
Accounts Payable 6813 6558
Notes Payable/Short Term Debt 168 149
Current Port. of LT Debt/Capital Leases 4287 3145
Other Current Liabilities, Total 12696 12208
Total Liabilities 51938 50875
Total Long Term Debt 17047 18134
Long Term Debt 15143 16133
Capital Lease Obligations 1904 2001
Deferred Income Tax 1841 1550
Minority Interest 368 353
Other Liabilities, Total 8718 8778
Total Equity 74784 70951
Common Stock 2522 2531
Additional Paid-In Capital 66859 555
Retained Earnings (Accumulated Deficit) 61883
Treasury Stock - Common -706 -1169
Other Equity, Total 6109 7151
Total Liabilities & Shareholders’ Equity 126722 121826
Total Common Shares Outstanding 1252.64 1252
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 8371 6223 12294 2754 4306
Cash From Operating Activities 10526 10522 7418 7715 5547
Cash From Operating Activities 3420 3351 3671 7445 4279
Deferred Taxes -578 -356 -221 -1772 -727
Non-Cash Items 20 -105 -8001 -293 -1031
Cash Taxes Paid 2452 1280 2051 1695 2058
Cash Interest Paid 380 334 315 379 412
Changes in Working Capital -707 1409 -325 -419 -1280
Cash From Investing Activities -2075 -7298 3619 -1029 -12872
Capital Expenditures -2201 -2043 -2083 -1787 -1977
Other Investing Cash Flow Items, Total 126 -5255 5702 758 -10895
Cash From Financing Activities -5821 -7056 -6485 -4193 3934
Financing Cash Flow Items -99 -48 -44 -21 -91
Total Cash Dividends Paid -4168 -4008 -3937 -3834 -3773
Issuance (Retirement) of Stock, Net -309 -196 -619 153 -924
Issuance (Retirement) of Debt, Net -1245 -2804 -1885 -491 8722
Foreign Exchange Effects 8 15 -64 9 1
Net Change in Cash 2638 -3817 4488 2502 -3390
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 8371 3184
Cash From Operating Activities 10526 3825
Cash From Operating Activities 3420 1820
Deferred Taxes -578 -404
Non-Cash Items 20 267
Cash Taxes Paid 2452 927
Cash Interest Paid 380 162
Changes in Working Capital -707 -1042
Cash From Investing Activities -2075 -1459
Capital Expenditures -2201 -974
Other Investing Cash Flow Items, Total 126 -485
Cash From Financing Activities -5821 -5605
Financing Cash Flow Items -99 -69
Total Cash Dividends Paid -4168 -4168
Issuance (Retirement) of Stock, Net -309 -320
Issuance (Retirement) of Debt, Net -1245 -1048
Foreign Exchange Effects 8 40
Net Change in Cash 2638 -3199
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
L'Oreal SA Corporation 9.3672 118227307 0 2023-01-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 7.3542 92820373 -109952 2022-12-01 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.6227 33101922 275247 2023-04-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.1046 26563280 1278355 2022-12-31 LOW
Sanofi SA Employees Corporation 2.0112 25384441 -502060 2023-01-31 LOW
Dodge & Cox Investment Advisor/Hedge Fund 1.9805 24996804 -38447917 2022-12-31 LOW
Amundi Asset Management, SAS Investment Advisor/Hedge Fund 1.7093 21574287 -49732 2023-04-30 MED
T. Rowe Price Associates, Inc. Investment Advisor 1.3742 17344626 -233 2022-12-01 LOW
Fidelity International Investment Advisor 0.9794 12360920 -275605 2023-03-31 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.9046 11416977 -61760 2023-04-30 LOW
Mellon Investments Corporation Investment Advisor/Hedge Fund 0.8696 10976049 9625458 2022-11-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7484 9446072 -3499 2023-04-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.687 8670792 69 2023-04-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 0.6778 8554174 -47826 2023-04-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.6157 7770600 31042 2023-03-31 LOW
DWS Investment GmbH Investment Advisor/Hedge Fund 0.576 7269728 20328 2023-04-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.5352 6755031 -165288 2023-03-31 LOW
BNP Paribas Asset Management France SAS Investment Advisor/Hedge Fund 0.5247 6622974 93156 2023-04-30 LOW
First Eagle Investment Management, L.L.C. Investment Advisor/Hedge Fund 0.5245 6620194 -1970 2023-03-31 LOW
Schroder Investment Management Ltd. (SIM) Investment Advisor/Hedge Fund 0.4129 5211829 -127 2023-04-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

530K+

Traders

87K+

Active clients monthly

$46M+

Monthly investing volume

$31M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Sanofi Company profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
Industry: Pharmaceuticals (NEC)

46 Avenue de la Grande Armée
PARIS
ILE-DE-FRANCE 75017
FR

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

67.55 Price
-2.750% 1D Chg, %
Long position overnight fee -0.0155%
Short position overnight fee -0.0064%
Overnight fee time 21:00 (UTC)
Spread 0.03

BTC/USD

27,078.95 Price
-2.510% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

US100

14,331.30 Price
-0.190% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.51 Price
-3.230% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00397

Still looking for a broker you can trust?

Join the 530.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading